Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE HealthCare (NASDAQ: GEHC) to develop peripheral focused ultrasound (PFUS) technology. This non-invasive approach aims to regulate metabolic function in the treatment of chronic diseases such as type 2 diabetes (T2D) and obesity.
PFUS Technology and Its Potential
The bioelectronic technique is designed to stimulate the nervous system and has demonstrated potential to impact glucose metabolism, helping to normalize blood glucose levels. Pre-clinical and early-stage clinical studies have shown promising results, indicating the technology’s potential in managing metabolic disorders.
Financial Terms of the Partnership
The financial details of the partnership were not disclosed, reflecting a focus on the collaborative development of this innovative technology rather than immediate financial gains. The collaboration aims to leverage the strengths of both companies to bring a novel treatment option to patients suffering from chronic metabolic diseases.-Fineline Info & Tech
